28 May 2014 : Case report
Interferon-alpha-induced sarcoidosis in a patient being treated for hepatitis C
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Remi TrienABCDEF, Chad J. CooperABCDEF, David PaezCDE, Edgardo ColonDEF, Shajeea AjmalDEF, Hasan SalamehABCDEFDOI: 10.12659/AJCR.890180
Am J Case Rep 2014; 15:235-238
Abstract
BACKGROUND: IFN-alpha-2b in combination with ribavirin is now the standard of care for the treatment of hepatitis C. Sarcoidosis is a chronic multisystem granulomatous disorder characterized by noncaseating granulomas in the involved organs. The pathologic hallmark of sarcoidosis is the presence of noncaseating granulomas in the interstitium that typically involve the lymphatics.
CASE REPORT: A 43-year-old woman presented to our care with 2-week history of nausea, vomiting, diarrhea, shortness of breath, migraine headache, maculopapular rash, generalized weakness, and lightheadedness. She had been treated for hepatitis C with telaprevir, ribavirin, and interferon-alpha-2b for 6 months. Chest radiograph showed bilateral diffuse prominence of bronchovascular markings. CT of the chest revealed bilateral diffuse centrilobular nodules with associated intralobular septal thickening, thickening of the central peribronchovascular interstitium, nodularity of the major fissures, and mediastinal lymphadenopathy. These findings were suspicious for atypical pulmonary sarcoidosis, possibly interferon-induced. The pathology of the mediastinal lymph node biopsy revealed noncaseating granulomatous inflammation consistent with the diagnosis of pulmonary sarcoidosis. Pathology of the skin punch biopsy showed giant-cell granulomatous inflammation without necrosis. The patient was started on prednisone 40 mg daily with a steroid tapering course for 8 weeks.
CONCLUSIONS: The management of IFN-induced sarcoidosis includes the discontinuation of IFN therapy with or without the administration of systemic corticosteroids. With the increasing prevalence of HCV in the United States, it is likely that more IFN-alpha-induced sarcoidosis will be encountered by clinicians.
Keywords: Hepatitis C, Interferons - adverse effects, Sarcoidosis - chemically induced
In Press
Case report
Takotsubo Syndrome-Induced Cardiogenic Shock in Lung Transplantation: Importance of Early Diagnosis and ECM...Am J Case Rep In Press; DOI: 10.12659/AJCR.944942
Case report
Priapism Following Coronary Angiography: A Case Report and Clinical Insights for Diagnosis and ManagementAm J Case Rep In Press; DOI: 10.12659/AJCR.943609
Case report
Anterior Mitral Line Ablation-Induced Complete Heart Block: A Cautionary Case StudyAm J Case Rep In Press; DOI: 10.12659/AJCR.945818
Case report
Dual-Plate Fixation in Treatment of Clavicle Fractures in Dementia Patients: A Case SeriesAm J Case Rep In Press; DOI: 10.12659/AJCR.945489
Most Viewed Current Articles
21 Jun 2024 : Case report 72,630
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 44,111
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 32,596
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
23 Feb 2022 : Case report 20,506
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250